SLDB — Solid Biosciences Share Price
0.000.00%
Last trade - 00:00- $339.06m
- $217.12m
- 30
- 17
- 90
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.68 | ||
| Price to Tang. Book | 2.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.31% | ||
| Return on Equity | -56.79% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 13.62 | 8.09 | n/a | 4.14 | 4.67 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Directors
- Ian Smith CHM (55)
- Ilan Ganot PRE (47)
- Stephen Dipalma CFO (62)
- Joel Schneider COO (36)
- Carl Morris CSO (51)
- Iman Barilero OTH
- Erin Brennan SEC (50)
- Adam Stone LED (42)
- Clare Kahn DRC (69)
- Martin Freed IND (60)
- Robert Huffines IND (56)
- Georgia Keresty IND (60)
- Adam Koppel IND (51)
- Sukumar Nagendran IND (55)
- Rajeev Shah IND (43)
- Lynne Sullivan IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 4th, 2013
- Public Since
- January 26th, 2018
- No. of Shareholders
- 57
- No. of Employees
- 88
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 37,756,877
- Address
- 500 RUTHERFORD AVENUE, 3RD FLOOR, CHARLESTOWN, 02129
- Web
- https://www.solidbio.com/
- Phone
- +1 6173374680
- Contact
- Leah Monteiro
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for SLDB
Solid Biosciences Inc Annual Shareholders Meeting
Solid Biosciences Inc Annual Shareholders Meeting
Q2 2024 Solid Biosciences Inc Earnings Release
Similar to SLDB
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Solid Biosciences share price?
As of Today at 07:20 UTC, shares in Solid Biosciences are trading at $8.98. This share price information is delayed by 15 minutes.
How has the Solid Biosciences share price performed this year?
Shares in Solid Biosciences last closed at $8.98 and the price had moved by +85.15% over the past 365 days. In terms of relative price strength the Solid Biosciences share price has outperformed the S&P500 Index by +51.37% over the past year.
What are the analyst and broker recommendations for Solid Biosciences?
The overall consensus recommendation for Solid Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Solid Biosciences dividend yield?
Solid Biosciences does not currently pay a dividend.
Does Solid Biosciences pay a dividend?
Solid Biosciences does not currently pay a dividend.
When does Solid Biosciences next pay dividends?
Solid Biosciences does not currently pay a dividend.
How do I buy Solid Biosciences shares?
To buy shares in Solid Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Solid Biosciences?
As of the previous close price of $8.98, shares in Solid Biosciences had a market capitalisation of $339.06m.
Where are Solid Biosciences shares listed?
Here are the trading details for Solid Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SLDB
What kind of share is Solid Biosciences?
Based on an overall assessment of its quality, value and momentum Solid Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Solid Biosciences share price forecast for 2024?
The analyst consensus target price for shares in Solid Biosciences is $17.00. That is 89.31% above the last closing price of $8.98.
Analysts covering Solid Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$2.66 for the next financial year.
What is the trend in the Solid Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Solid Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +288.2%.
As of the last closing price of $8.98, shares in Solid Biosciences were trading +51.04% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Solid Biosciences PE Ratio?
The Solid Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Solid Biosciences?
Solid Biosciences' management team is headed by:
- Ian Smith - CHM
- Ilan Ganot - PRE
- Stephen Dipalma - CFO
- Joel Schneider - COO
- Carl Morris - CSO
- Iman Barilero - OTH
- Erin Brennan - SEC
- Adam Stone - LED
- Clare Kahn - DRC
- Martin Freed - IND
- Robert Huffines - IND
- Georgia Keresty - IND
- Adam Koppel - IND
- Sukumar Nagendran - IND
- Rajeev Shah - IND
- Lynne Sullivan - IND